Nucleus Genomics offers whole genome sequencing to consumers and emphasizes long-form health interpretation of the results. If you have Nucleus WGS data and want a dedicated pharmacogenetic analysis covering 103 medications with CPIC- and FDA-anchored recommendations, Gene2Rx reads your Nucleus VCF and produces the full report in minutes. This guide explains what WGS buys you for pharmacogenetics and how Gene2Rx works with Nucleus data specifically.
Pharmacogenetic reports inform prescribing decisions but do not replace clinical judgment. Never start, stop, or change medications based solely on a report.
Nucleus Genomics markets itself as a consumer WGS service with integrated health insights. Their pharmacogenetic coverage has been expanding, but if you want a dedicated, CPIC-anchored pharmacogenetic report covering 103 medications across all major drug classes (not just the highlights in Nucleus's built-in reports), running your VCF through a service specifically designed for pharmacogenetic analysis gives you the deepest coverage.
Consumer genotyping arrays (23andMe, AncestryDNA) cover common pharmacogenetic variants but miss rare variants and struggle with CYP2D6 star-allele resolution (especially copy-number variants). Whole genome sequencing reads every position, so if you have Nucleus WGS you have better PGx substrate than 90 percent of consumer genetic data out there. Gene2Rx is designed to extract maximum value from WGS VCFs.
A report covering 103 medications with phenotype-level recommendations from CPIC and FDA guidelines, including psychiatric medications (SSRIs, TCAs, antipsychotics), cardiovascular drugs (clopidogrel, warfarin, statins, metoprolol), pain medications, chemotherapy, immunosuppressants, gastroenterology (PPIs), and more. Each drug gets a specific recommendation tied to your metabolizer phenotype, with source citation to the relevant published guideline.
Download your Nucleus VCF file from your Nucleus account. Upload it to Gene2Rx. Receive the pharmacogenetic report in minutes. The Gene2Rx pipeline handles both GRCh37 and GRCh38 reference genomes, so you don't need to pre-process the file. Report tiers range from $5 to about $64, with WGS processing carrying a small additional fee over consumer genotyping data because of the computational cost of parsing full-genome VCFs.
Pharmacogenes where WGS data gives you a meaningful edge over consumer array data.
The most clinically variable pharmacogene. Its phenotype depends on gene copy number (duplications, deletions) as well as single-nucleotide variants, and genotyping arrays struggle to capture copy-number variation. WGS resolves CYP2D6 properly and delivers more accurate metabolizer calls.
Critical for fluoropyrimidine chemotherapy (5-FU, capecitabine). Severe DPYD deficiency is rare but lethal at standard chemotherapy doses. WGS captures the full set of DPYD variants including rare ones that consumer arrays miss.
Determines thiopurine drug safety (azathioprine, mercaptopurine). Loss-of-function variants are rare but clinically critical; WGS ensures you haven't missed any.
HLA-B*57:01 (abacavir) and HLA-B*15:02 (carbamazepine) are both fully resolvable from WGS. Consumer arrays often tag these correctly, but WGS gives full confidence in the call.
If you have Nucleus Genomics WGS data, running a dedicated pharmacogenetic analysis on it unlocks information that neither Nucleus's built-in reports nor any consumer-array-based test can match for completeness.
Whenever you have WGS data sitting around, pharmacogenetic analysis is one of the highest-signal uses of it. The results are valid for life, inform every medication decision, and don't need to be re-run when your prescriptions change.
Learn how genetics may affect your response to these related medications:
Yes. Nucleus provides access to your raw sequencing data including a VCF file. The exact export path depends on your Nucleus subscription tier; check your account for the download option.
Nucleus offers integrated health interpretation covering a broad range of topics. Gene2Rx is specifically focused on pharmacogenetics and covers more medications (103) with CPIC-anchored per-phenotype recommendations. They can complement each other: Nucleus for broad health insights, Gene2Rx for a pharmacogenetic deep-dive on your medications.
For the CPIC-defined phenotype calls, yes. The underlying genetic variants are the same whether sequenced by Nucleus, a clinical lab, or any other reputable WGS provider. The interpretation follows the same CPIC and FDA guidelines. The distinction between Gene2Rx and a clinical test like GeneSight is about workflow (direct-to-consumer vs prescriber-ordered) and medication breadth, not about accuracy of the phenotype calls.
Find out how your DNA may influence your response to Sertraline and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator